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 ORIGINAL ARTICLE 
 Increased primary health care use in the fi rst year after colorectal 
cancer diagnosis 
 DAAN  BRANDENBARG 1 ,  CARRIENE  ROORDA 1 ,  FEIKJE  GROENHOF 1 , 
 KLAAS  HAVENGA 2 ,  MARJOLEIN Y.  BERGER 1 ,  GEERTRUIDA H.  DE BOCK 3 
 &  ANNETTE J.  BERENDSEN 1 
 1 Department of General Practice, University Medical Center Groningen, University of Groningen, Groningen, 
The Netherlands,  2 Department of Surgery, Division of Abdominal Surgery, University Medical Center Groningen, 
University of Groningen, Groningen, The Netherlands,  3 Department of Epidemiology, University Medical Center 
Groningen, University of Groningen, Groningen, The Netherlands 
 Abstract 
 Objective. The view that the general practitioner (GP) should be more involved during the curative treatment of cancer is 
gaining support. This study aimed to assess the current role of the GP during treatment of patients with colorectal cancer 
(CRC).  Design. Historical prospective study, using primary care data from two cohorts.  Setting. Registration Network 
Groningen (RNG) consisting of 18 GPs in three group practices with a dynamic population of about 30 000 patients. 
 Subjects. Patients who underwent curative treatment for CRC (n    124) and matched primary care patients without CRC 
(reference population; n    358).  Main outcome measures. Primary healthcare use in the period 1998 – 2009.  Findings . Patients 
with CRC had higher primary healthcare use in the year after diagnosis compared with the reference population. After 
correction for age, gender, and consultation behaviour, CRC patients had 54% (range 23 – 92%) more face-to-face contacts, 
68% (range 36 – 108%) more drug prescriptions, and 35% (range  – 4 – 90%) more referrals compared with reference patients. 
Patients consulted their GP more often for reasons related to anaemia, abdominal pain, constipation, skin problems, and 
urinary infections. GPs also prescribed more acid refl ux drugs, laxatives, anti-anaemic preparations, analgesics, and psyc-
holeptics for CRC patients.  Conclusions. The GP plays a signifi cant role in the year after CRC diagnosis. This role may be 
associated with treatment-related side effects and psychological problems. Formal guidelines on the involvement of the GP 
during CRC treatment might ensure more effective allocation and communication of care between primary and secondary 
healthcare services. 
 Key Words:  Colorectal cancer ,  general practitioners ,  healthcare use ,  primary health care ,  The Netherlands 
Internationally, there is increasing support for the 
idea that GPs (and other primary care providers) 
should be more involved in all stages of cancer care 
[6 – 10]. 
 In the Dutch guideline on colorectal cancer 
(CRC) [11] no formal role is described for the GP 
during treatment. Moreover, healthcare use of CRC 
patients in primary care during treatment has not yet 
been studied. In a Dutch study on patients with 
breast cancer, increased contact rates with the GP 
were observed in the fi rst year after diagnosis when 
compared with a reference population [12]. Similar 
 Introduction 
 In countries where the general practitioner (GP) 
acts as a gatekeeper to the healthcare system, the GP 
traditionally plays an important role for patients 
with cancer: in early detection [1,2], managing 
comorbidities and psychosocial issues [3], and pal-
liative care [4]. In the Netherlands, the expected 
increase in the prevalence of cancer is likely to impose 
a considerable burden on the healthcare system 
[5]. According to the Dutch Cancer Society, this 
highlights the need for an effective resource alloca-
tion between primary care and secondary care [6]. 
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56 D. Brandenbarg et al. 
fi ndings were reported in a study conducted in 
Denmark concerning all cancer types [13], but the 
reasons associated with health care use were not 
examined in this study. 
 Treatment-related side effects of surgical treat-
ment for CRC, chemotherapy, and radiotherapy may 
have a major impact on patients ’ lives and perceived 
quality of life [14,15]. Whereas the role of the GP in 
diagnostic and referral pathways of CRC has been 
extensively studied [2], little is known about the 
effect of CRC treatment and its side effects on 
patients ’ healthcare use in primary care. Therefore, 
the aim of the current study is to assess the GP ’ s role 
during curative treatment of patients with CRC by 
an analysis of health care use in the fi rst year after 
diagnosis. 
 Material and methods 
 Design and setting 
 Healthcare use of patients during the fi rst year after 
CRC diagnosis was compared with an age- and 
gender-matched reference population from the same 
general practice, in a historical prospective study. 
Healthcare utilization data were extracted from the 
database of the Registration Network Groningen 
(RNG). This GP registration network, founded in 
1989, collects data from 18 GPs in three group prac-
tices in the northern part of the Netherlands with 
about 30 000 patients [16]. In accordance with the 
privacy instructions of the RNG, anonymized patient 
records were used. Because the study was in agree-
ment with the regulations for publication of routinely 
registered healthcare data, no further offi cial approval 
was required. 
 Participants and data collection 
 The study population was determined by selecting 
RNG patients with a fi rst diagnosis of CRC between 
1998 and 2009, using the D75 code (colon or rectum 
malignity) of the International Classifi cation of 
Primary Care (ICPC) version 1 [17]. The date of 
referral by the GP was used as the date of diagnosis. 
When unavailable, the fi rst date of recording the 
D75 code (39.6% of cases) in the electronic patient 
record was used. The CRC diagnosis was validated 
in the GPs ’ practices and additional information 
about the CRC stage, treatment, and recurrence was 
retrieved by examining specialist reports and hospi-
tal records. Figure 1 shows the process of identifi ca-
tion and inclusion of study patients. Patients with a 
CRC diagnosis before 1998 (n    90) were excluded 
because the recording of healthcare use by the RNG 
before 1998 was unavailable. Patients not treated 
with curative intent (n    70) were also excluded, 
because palliative treatment of cancer is likely to 
generate excessive or atypical healthcare use in 
primary care [18]. 
 A reference population of patients without CRC 
was identifi ed in the RNG database. Each CRC 
patient was individually matched (if possible) with 
three patients (with a minimum of one) on gender, 
age (   1 year), and GP to control for recording and 
prescribing by GPs and for regional factors such as 
socioeconomic status. Four patients with CRC could 
not be matched with at least one patient from the 
reference population and were excluded. Also, eight 
patients and their references were excluded from 
data analysis because the patients were not registered 
at the GP ’ s offi ce at the time of diagnosis. 
 This study is the fi rst to analyse disease-specifi c 
primary health care use of patients treated with 
curative intent in the fi rst year following 
diagnosis of colorectal cancer (CRC). 
 The general practitioner plays a signifi cant  •
role in the year after CRC diagnosis. 
 CRC patients show higher primary health  •
care use compared with the reference popu-
lation in the fi rst year after diagnosis. 
 This higher health care use may be associ- •
ated with treatment-related side effects and 
psychological problems. 
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 Finally, 124 patients with CRC and 358 reference 
patients were available for analysis. Data collected 
were entered in an anonymized database and con-
sisted of patient contacts recorded by the GPs using 
ICPC codes, prescribed medication automatically 
classifi ed according to the Anatomical Therapeutical 
Chemical (ATC) classifi cation [19], and referrals 
(in which the CRC referral was included). 
 Data analysis 
 Database management and statistical analyses were 
performed in Microsoft Access 2010 and IBM SPSS 
version 20, respectively. Due to the skewed distribu-
tion of the data, statistical analyses were performed 
using non-parametric tests and negative binomial 
regression analysis. To compare characteristics 
between patients and the reference population, the 
Mann – Whitney U-test was used. 
 Annual healthcare utilization rates in the year 
after diagnosis were calculated by dividing the num-
ber of face-to-face contacts, drug prescriptions, and 
referrals by the observation time. Face-to-face con-
tacts consisted of consultations in general practice, 
as well as visits to patients ’ homes made by GPs or 
other general practice workers. The annual health-
care utilization rates in the year prior to diagnosis 
were also calculated to allow for a comparison with 
utilization rates after diagnosis. Differences in median 
face-to-face contact, drug prescription, and referral 
rates between CRC patients and the reference popu-
lation were analysed using the Mann – Whitney test. 
Wilcoxon ’ s signed rank test was used to compare the 
healthcare use before and after diagnosis within the 
two groups. 
 To assess the size of the difference in healthcare 
use after diagnosis between CRC patients and the 
reference population, a multivariate negative bino-
mial regression analysis was performed. To adjust for 
patients ’ gender, age, and healthcare utilization rates 
before diagnosis, these variables were included in the 
model. Differences in observation time were 
accounted for by including the log-transformed 
observation time since diagnosis as an offset variable 
in the model. 
 A univariate negative binomial regression analysis 
was performed to evaluate whether specifi c charac-
teristics of CRC patients (gender, age, TNM stage, 
and received therapy) were associated with higher 
rates of face-to-face contacts, prescribed medication, 
and referrals since diagnosis. 
 To examine reasons for primary healthcare use, 
numbers and percentages of CRC patients and the 
reference population with any face-to-face contact by 
ICPC code and any drug prescription by ATC code 
in the year after diagnosis were calculated. Differ-
ences in reasons for primary healthcare use between 
CRC patients and the reference population based on 
ICPC codes were tested with the Chi-square test. 
 Results 
 Characteristics of patients with CRC (n    124) and 
the reference population (n    358) are presented in 
 Table I. Characteristics of the patients with colorectal cancer (n    124) and the reference 






Male 63 (50.8) 181 (50.6)
Female 61 (49.2) 177 (49.4)
Age at diagnosis in years, median (range) 69.3 (36.4 – 91.1) 68.6 (36.6 – 91.6)












Observation time in days, median (range):
Period before diagnosis 365 (1 – 365) 365 (8 – 365) 0.125 1 
Period since diagnosis 365 (218 – 365) 365 (26 – 365) 0.265 1 



























































58 D. Brandenbarg et al. 
Table I. Median age at diagnosis was 69.3 (range 
36.4 – 91.1) years. 
 Table II shows the annual healthcare utilization 
rates and numbers and percentages with at least 
one contact/prescription/referral of patients and the 
reference population in the period before and after 
CRC diagnosis. Patients had signifi cantly more 
face-to-face contacts, prescriptions, and referrals 
compared with the reference population (Mann – 
Whitney test, p    0.01) in both the year before and 
after diagnosis. Face-to-face contact rates and pre-
scription rates showed a signifi cant increase after 
diagnosis (Wilcoxon signed rank test, p    0.01) in 
patients and in the reference population. Signifi cantly 
more patients had at least one contact and referral 
before diagnosis, and signifi cantly more patients had 
at least one contact, prescription, and referral after 
diagnosis (Chi-square test). 
 When corrected for age, gender, and healthcare 
use before diagnosis, results of the multiple negative 
binomial regression showed that patients had 54% 
more face-to-face contacts, 68% more drug prescrip-
tions, and 35% more referrals in the year after diag-
nosis compared with the reference population 
(Table III). 
 Furthermore, univariate negative binomial regres-
sion analysis showed that only a higher age was asso-
ciated with more face-to-face contacts after diagnosis. 
Higher rates of prescribed medication and referrals 
before diagnosis were associated with these rates 
after diagnosis. None of the other patient character-
istics (as shown in Table I) were associated with 
higher healthcare use after diagnosis (data not 
shown). 
 Table IV presents the reasons for GP contacts 
and the prescribed medication in the year after diag-
nosis for CRC patients and the reference population. 
Signifi cantly more patients contacted their GP for 
anaemia, abdominal pain, constipation, and urinary 
infections. Signifi cantly more patients than those 
from the reference population were prescribed the 
following medication: acid refl ux drugs and laxatives, 
mineral supplements, anti-anaemic preparations, 
analgesics, psycholeptics (mainly hypnotics and 
sedatives), and cough/cold preparations. 
 Discussion 
 This study explored the involvement of the GP dur-
ing curative treatment of CRC. Patients showed 
higher healthcare use in primary care in the year after 
diagnosis compared with the reference population, 
and also compared with their healthcare use before 
diagnosis. Adjusted for gender, age, and healthcare 
use before diagnosis, patients had 54% more face-to-
face contacts, 68% more drug prescriptions, and 
35% more referrals after diagnosis compared with 
 Table III. Rate ratios and 95% confi dence intervals (CI) 
for face-to-face contacts, drug prescriptions, and referrals 
for patients with colorectal cancer in the year after diagnosis 
compared with the reference population. 
Rate ratio 95% CI
Face-to-face contacts:
Reference population 1
Patients 1.54 1.23 – 1.92
Drug prescriptions:
Reference population 1
Patients 1.68 1.36 – 2.08
Referrals:
Reference population 1
Patients 1.35 0.96 – 1.90
 Note: Adjusted for: gender, age, and healthcare utilization rates 
before diagnosis. The number of face-to-face contacts, drug 
prescriptions, and referrals before diagnosis were included in the 
model when analysing these three variables after diagnosis. Log-
transformed observation time was included in the model as an 
offset variable. 
 Table II. Annual healthcare utilization rates before and after diagnosis for patients with colorectal cancer (CRC) (n    124) 
and the reference population (n    358). 
Annual healthcare use






Face-to-face contacts, median (range) 5.0 (0.0 – 60.8) 1 3.0 (0.0 – 30.0) 6.0 (0.0 – 44.0) 2,3 3.0 (0.0 – 45.6) 4 
At least one face-to-face contact, n (%) 111 (89.5) 1 286 (79.9) 122 (98.4) 2 303 (84.6)
Drug prescriptions, median (range) 13.0 (0.0 – 95.0) 1 9.0 (0.0 – 284.0) 16.5 (0.0 – 88.0) 2,3 9.0 (0.0 – 297.6) 4 
At least one drug prescription, n (%) 111 (89.5) 307 (85.8) 121 (97.6) 2 309 (86.3)
Referrals, median (range) 0.0 (0.0 – 4.0) 1 0.0 (0.0 – 4.1) 0.0 (0.0 – 4.5) 0.0 (0.0 – 6.0)
At least one referral, n (%) 48 (38.7) 1 95 (26.5) 56 (45.2) 2 113 (31.6)
 Notes: Rates or percentages were signifi cantly different between patients and reference population, Mann – Whitney test or Chi-square test, 
p    0.05.  1 Before diagnosis.  2 After diagnosis. Rates showed a signifi cant increase after diagnosis, Wilcoxon signed rank test, p    0.05.  3 Within 
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the reference population. Neither treatment nor 
tumour stage was associated with higher healthcare 
use. More patients consulted their GP for reasons 
related to anaemia, abdominal pain, constipation, 
skin problems, and urinary infections compared with 
the reference population. GPs also prescribed more 
acid refl ux drugs, laxatives, anti-anaemic prepara-
tions, analgesics, and psycholeptics (mainly hypnot-
ics and sedatives). 
 A major strength of this study is the use of a 
prospective primary care database to analyse and 
compare the healthcare use of patients with and 
without CRC. The presentation of healthcare prob-
lems was recorded by the GPs of the registration 
network, making recall or non-response bias less 
likely than in self-reported survey data [20]. By 
matching on GP, any inaccuracies in recording and 
prescribing were evenly distributed among CRC 
patients and the reference population [12]. Revali-
dating the data with specialist reports in GPs ’ prac-
tices and available hospital records increased the 
likelihood that the patient information was correctly 
recorded by the GP. 
 In the Netherlands almost every inhabitant is reg-
istered with a GP [21]. Therefore the RNG database 
is population-based. This population is comparable 
to the Dutch population in terms of gender and age 
with slightly more adults aged 25 – 44 and women 
[22]. Nevertheless, care provided by the 18 GPs 
on the RNG might differ from other GPs in the 
Netherlands, possibly limiting the generalizability of 
the study results. Another limitation of the current 
study is the small number of patients, limiting the 
statistical power to fi nd signifi cant associations 
between patients ’ characteristics and higher health 
care use. The fi nding that CRC patients have higher 
healthcare use in the year after diagnosis compared 
with the reference population is in line with an earlier 
Dutch study among patients with breast cancer and 
a Danish study among patients with all types of 
cancer [12,13]. Although not a focus of the present 
study, our fi ndings show that CRC patients also have 
higher healthcare use during the year before diagno-
sis. This elevated healthcare use before diagnosis was 
not observed in patients with breast cancer [12]. This 
might be due to the fact that, in contrast to breast 
cancer symptoms, most symptoms associated with 
CRC are common and relatively innocent, and 
because single symptoms have a low predictive 
value for CRC [2]. In the Danish study an increase 
 Table IV. Reasons for primary healthcare use among patients with colorectal cancer (CRC) (n    124) and patients from 





Number of patients with at least one face-to-face contact by ICPC chapter: 
General and unspecifi ed (A) * * 51 (41.1) 80 (22.3)
No illness (A97) * 16 (12.9) 21 (5.9)
Blood, blood-forming organs and immune mechanism (B) * * * 17 (13.7) 10 (2.8)
Anaemia (B80) * * * 14 (11.3) 3 (0.8)
Digestive (D) * * * 113 (91.1) 72 (20.1)
Abdominal pain localized other (D06) * * * 17 (13.7) 10 (2.8)
Constipation (D12) * 11 (8.9) 10 (2.8)
Colon or rectum malignity (D75) * * * 101 (81.5) 0 (0.0)
Malign neoplasm digestive system other (D77) * * * 9 (7.3) 0 (0.0)
Skin (S) * 44 (35.5) 82 (22.9)
Urological (U) * 25 (20.2) 41 (11.5)
Cystitis/urinary infection other (U71) * 17 (13.7) 25 (7.0)
Number of patients with at least one prescription by ATC chapter:
Alimentary tract and metabolism (A) * * * 80 (64.5) 130 (36.1)
Drugs for acid-related disorders (A02) * * * 44 (35.5) 66 (18.4)
Drugs for functional gastrointestinal disorders (A03) * 15 (12.1) 17 (4.7)
Drugs for constipation (A06) * * * 35 (28.2) 52 (14.5)
Mineral supplements (A12) * * * 14 (11.3) 17 (4.7)
Blood and blood-forming organs (B) * * * 58 (46.8) 105 (29.3)
Anti-anaemic preparations (B03) * * * 25 (20.2) 15 (4.2)
Nervous system (N) * * * 77 (62.1) 129 (36.0)
Analgesics (N02) * 34 (27.4) 61 (17.0)
Psycholeptics (N05) * * * 57 (46.0) 78 (21.8)
Respiratory system (R) * 37 (29.8) 73 (20.4)
Cough and cold preparations (R05) * 12 (9.7) 15 (4.2)
 No signifi cant differences were observed for the other ICPC and ATC chapters (see Appendix). Chi-square test:  * p    0.05, * * p    0.005, 



























































60 D. Brandenbarg et al. 
in primary healthcare use was also seen three months 
before diagnosis [13]. Future research should further 
examine contact frequency and reasons associated 
with higher healthcare use in CRC patients in the 
period prior to diagnosis. The elevated healthcare use 
before diagnosis might also be explained by a higher 
prevalence of comorbidity in CRC patients. 
 According to our fi ndings, received treatment 
and CRC staging were not associated with higher 
healthcare use in primary care after diagnosis. Prob-
lems associated with more aggressive treatments or 
more advanced cancer may be presented more in 
secondary care than in primary care. 
 The increased contact frequency for constipation, 
pain, micturition problems, and psychological prob-
lems might be related to the surgical therapy for 
CRC [23 – 26]. The aforementioned reasons for GP 
contacts and prescribed medication may also be 
related to chemotherapy (often associated with 
adverse effects such as nausea and diarrhoea) [27,28] 
or to radiotherapy (rectal bleeding, pain, bowel and 
urinary problems) [29,30]. Comorbidity is known to 
affect healthcare use [10]. However, analysis of the 
reasons for primary healthcare use based on the 
ICPC and ATC codes did not show increased health-
care use for chronic comorbidities, such as cardio-
vascular diseases, diabetes mellitus, and chronic 
obstructive pulmonary disease (COPD). Therefore, 
it is unlikely that the differences between the CRC 
patients and the reference population are due to dif-
ferences in comorbidity. 
 Although no formal role has been established, 
the GP is involved in the treatment of problems 
associated with the side effects of curative CRC 
treatment. Furthermore, the GP is involved in the 
prescription of hypnotics and sedatives. The view 
that GPs and other primary care physicians should 
play a more formal role in all stages of cancer care 
is gaining support. Formal guidelines on the involve-
ment of the GP during CRC treatment might ensure 
a more effective allocation and communication of 
care between primary and secondary healthcare 
services. 
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 Appendix: Overview of ICPC and ATC chapters. 
ICPC
 General and unspecifi ed (A)










 Endocrine, metabolic, and nutritional (T)
 Urological (U)
 Pregnancy, childbearing, and family planning (W)
 Female genital (X)
 Social problems (Z)
ATC
 Alimentary tract and metabolism (A)
 Blood and blood-forming organs (B)
 Cardiovascular system (C)
 Dermatologicals (D)
 Genito-urinary system and sex hormones (G)
 Systemic hormonal preparations, excl. sex hormones and 
insulins (H)
 Anti-infectives for systemic use (J)
 Antineoplastic and immunomodulating agents (L)
 Musculoskeletal system (M)
 Nervous system (N)
 Antiparasitic products, insecticides, and repellents (P)
 Respiratory system (R)
 Sensory organs (S)
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